Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.
Infinity Pharmaceuticals Inc. 0.00% $90.76 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback